Previous 10 | Next 10 |
SEATTLE, March 18, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced it will report full year 2020 financial re...
SEATTLE, March 02, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Execut...
SEATTLE, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executi...
Neoleukin is a leader in de novo drug design. The company's lead asset was recently put on clinical hold, pending more dosing data, creating a window to buy the stock. The company has the platform potential to expand their pipeline to a wide-range of protein therapeutics for cancer an...
Neoleukin Therapeutics (NASDAQ: NLTX) , a clinical-stage biopharmaceutical company, is not ending the week on a positive note. Shares of the drugmaker are dropping sharply on Friday and are down by 10.9% as of 12:33 p.m. EST, after plunging by as much as 21.7% earlier today. The cat...
Gainers: Chimerix (CMRX) +59%. Jaguar Health (JAGX) +36%. Medigus (MDGS) +23%. Merus (MRUS) +22%. SCWorx (WORX) +20%.Losers: Sarepta Therapeutics (SRPT) -50%. SOS (SOS) -42%. Neoleukin Therapeutics (NLTX) -15%. Bionano Genomics (BNGO) -14%. Solid Biosciences (SLDB) -12%. For furth...
Sarepta Therapeutics (SRPT) -48% as DMD gene therapy treatment fails to meet primary endpoint.Neoleukin Therapeutics (NLTX) -19% after receiving clinical hold letter from FDA related to CMC assay development for NL-201.Solid Biosciences (SLDB) -18% after Sarepta ...
Neoleukin Therapeutics (NLTX) drops ~20% in premarket trading after receiving a clinical hold from the FDA related to its Investigational New Drug ((IND)) application to start a Phase 1 program of its immunotherapeutic candidate, NL-201.The FDA has asked the company to develop a new...
SEATTLE, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that on January 7, 2021, it received a clin...
SEATTLE, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief E...
News, Short Squeeze, Breakout and More Instantly...
Neoleukin Therapeutics Inc. Company Name:
NLTX Stock Symbol:
NYSE Market:
SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its B...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Neoleukin Therapeutics Inc. (NLTX) is expected to report $-0.8 for Q3 2023